Liver function may change how cough drug works
NCT ID NCT06222892
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how camlipixant, an experimental drug for chronic cough, behaves in people with liver problems compared to healthy volunteers. 32 adults aged 18-75 took part to see if liver impairment changes drug levels or safety. The goal is to help doctors decide the right dose for patients with liver issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Miami, Florida, 33136, United States
-
GSK Investigational Site
Orlando, Florida, 32809, United States
-
GSK Investigational Site
San Antonio, Texas, 78215, United States